MARKET

IRON

IRON

Disc Medicine Inc
NASDAQ
80.00
-3.23
-3.88%
After Hours: 80.92 +0.92 +1.15% 19:30 11/13 EST
OPEN
83.00
PREV CLOSE
83.23
HIGH
83.00
LOW
79.73
VOLUME
779.95K
TURNOVER
--
52 WEEK HIGH
99.50
52 WEEK LOW
40.00
MARKET CAP
3.64B
P/E (TTM)
-12.6434
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Asahi Intecc Co (AHICF), Disc Medicine (IRON)
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: InMed Pharmaceuticals (INM), Disc Medicine (IRON) and Radnet (RDNT)
TipRanks · 5d ago
Disc Medicine Price Target Announced at $132.00/Share by Guggenheim
Dow Jones · 5d ago
Guggenheim Initiates Coverage On Disc Medicine with Buy Rating, Announces Price Target of $132
Benzinga · 5d ago
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON) and Immunic (IMUX)
TipRanks · 6d ago
Disc Medicine initiated with a Buy at Guggenheim
TipRanks · 6d ago
Disc Medicine’s Complementary Blood-Disorder Portfolio Supports Buy Rating and $132 Price Target
TipRanks · 6d ago
Weekly Report: what happened at IRON last week (1102-1106)?
Weekly Report · 6d ago
More
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Webull offers Disc Medicine Inc stock information, including NASDAQ: IRON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRON stock methods without spending real money on the virtual paper trading platform.